MaxCyte Inc
Change company Symbol lookup
Select an option...
MXCT MaxCyte Inc
SWKS Skyworks Solutions Inc
BHVN Biohaven Pharmaceutical Holding Company Ltd
FFBC First Financial Bancorp
CHRD Chord Energy Corp
ALBY Community Capital Bancshares Inc
SMIH Summit Healthcare Acquisition Corp
SLAB Silicon Laboratories Inc
NCLH Norwegian Cruise Line Holdings Ltd
SNMSF Spin Master Corp
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The Company has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The Company has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.

Closing Price
$5.78
Day's Change
-0.35 (-5.71%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.03
Day's Low
5.50
Volume
(Light)
Volume:
409,029

10-day average volume:
882,099
409,029

MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs

8:00 am ET July 12, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NASDAQ:MXCT),(LSE:MXCT),(LSE:MXCN), EQNX::TICKER_END MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announces the signing of a strategic platform license (SPL) with LG Chem Ltd., a globally diversified chemical company established in petrochemical, advanced materials and bio-technology, aiming to create new value for its customers based on science.

Under the terms of the agreement, LG Chem obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.

Further accelerating its efforts for clinical development of global new drugs, LG Chem is strengthening its anti-cancer sector through advanced construction of cell drug platform technologies. LR19023, the next-generation CAR-T cell treatment, is currently in the pre-clinical stage and under development as a solid cancer therapeutic.

Doug Doerfler, President and CEO of MaxCyte, said: "We are thrilled to partner with the global multinational company LG Chem to support their CAR T programs for solid tumors. This partnership represents our first SPL with a South Korean company and broadens our reach into Asia to provide advanced technologies that support the clinical and commercial development of engineered cell therapies, and ultimately change the lives of patients with cancer."

MaxCyte's ExPERT(TM) instrument portfolio is the next generation of leading, clinically-validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT(TM) platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. LG CHEM is MaxCyte's first SPL in Asia and 17th overall, which generate pre-commercial milestone revenue and the vast majority of which include post-commercial revenue.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation(R) platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT(TM) platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx(TM), STx(TM) and GTx(TM); a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser                                +1 415-937-5400
Gilmartin Group                              ir@maxcyte.com
David Deuchler, CFA
US Media Relations                           +1 408-497-8568
Valerie Enes                                 valerie@teamseismic.com
Seismic
Nominated Adviser and Joint Corporate Broker +44 (0)20 7886 2500
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
UK IR Adviser                                +44 (0)203 709 5700
Consilium Strategic Communications           maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh

https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png

https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png

comtex tracking

COMTEX_410027027/2010/2022-07-12T08:00:01

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.